What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Artiva Biotherapeutics, Inc. ARTV Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead SciencesGILD

$166M-34.1%

Kyverna Therapeutics, Inc.KYTX

$243K+8,000%

Allogene TherapeuticsALLO

$450K-95.5%

Immix Biopharma, Inc.IMMX

$33.53K—

ImmunityBio, Inc.IBRX

$971K+341%

Cullinan Therapeutics, Inc.CGEM

$0-100%

Other financials

Income statement

See full

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

See full

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

See full

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

See full

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

See full

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

See full

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Artiva Biotherapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s stock issuance proceeds?: Artiva Biotherapeutics, Inc. (ARTV) reported stock issuance proceeds of -$138K in Q4 2025.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.